Seres Therapeutics, Inc. (MCRB)

1,1600 +0,0500 (+4,50%) Börsenschluss: 04:00PM EDT

Seres Therapeutics, Inc.

101 Cambridgepark Drive
Cambridge, MA 02140
United States
617 945 9626
https://www.serestherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 233

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Eric D. Shaff M.B.A.	President, CEO & Director	1,02M	N/A	1976
Dr. Lisa von Moltke M.D.	Executive VP & Chief Medical Officer	725,15k	N/A	1959
Dr. Teresa L. Young Ph.D., R.Ph.	Executive VP and Chief Commercial & Strategy Officer	606,33k	N/A	1967
Ms. Marella Thorell	Executive VP & CFO	N/A	N/A	1967
Dr. David S. Ege Ph.D.	Executive VP & Chief Technology Officer	142,71k	N/A	1975
Dr. Matthew R. Henn Ph.D.	Executive VP & Chief Scientific Officer	643,83k	N/A	1975
Mr. Carlo Tanzi Ph.D.	Investor Relations Officer	N/A	N/A	N/A
Mr. Thomas J. DesRosier Esq., J.D.	Chief Legal Officer, Executive VP & Secretary	719,55k	N/A	1955
Ms. Caroline Holda	Assistant General Counsel	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Seres Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 3, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.